Effectiveness of Ivabradine Treatment in Different Subpopulations with Stable Angina in Clinical Practice: A Pooled Analysis of Observational Studies
| Autor: | Stefan Perings, Ralf Köster, Thomas Meinertz, Georg Stöckl, Karl Werdan, Malte Kelm, Ursula Müller-Werdan |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty Adrenergic beta-Antagonists 030204 cardiovascular system & hematology Stable angina Severity of Illness Index law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Quality of life law Heart Rate Internal medicine Severity of illness medicine Humans Pharmacology (medical) Ivabradine 030212 general & internal medicine Angina Stable Aged Aged 80 and over Nitrates business.industry Cardiovascular Agents Benzazepines Middle Aged Pooled analysis Treatment Outcome Cardiovascular agent Cardiology Quality of Life Observational study Drug Therapy Combination Female Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Cardiology. 135(3) |
| ISSN: | 1421-9751 |
| Popis: | Objectives: The efficacy of ivabradine has been demonstrated in different subpopulations of stable angina patients in randomized clinical trials. This study explored its effectiveness in subpopulations seen in clinical practice as they often differ from those of randomized trials. Methods: Data were pooled from three German observational studies with similar inclusion criteria (stable angina and heart rate ≥60 bpm). All patients received 2.5, 5, or 7.5 mg b.i.d. of ivabradine for 4 months, with or without concomitant beta-blocker. Antianginal effectiveness was analyzed in subpopulations defined by gender, age, heart rate, angina severity, use of concomitant beta-blocker, previous percutaneous coronary intervention procedure, and comorbidities (including previous myocardial infarction and diabetes). Results: Treatment data were available on 8,555 patients, where therapy with ivabradine was associated with a significant reduction in the frequency of angina attacks and consumption of short-acting nitrates of 87%. Effectiveness was maintained in all investigated subpopulations, with a reduction in antianginal parameters of 82-90%. Clinical status (Canadian Cardiovascular Society class) and quality of life were also improved. Ivabradine was well tolerated in all subgroups. Conclusions: Ivabradine is effective and safe in all subpopulations of angina patients seen in clinical practice, independent of age, comorbidities, and use of beta-blocker. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|